BARI: Panaxia Labs Israel Ltd - Summary | Jitta

Panaxia Labs Israel Ltd

ISR:BARI

Notice
Stock data is unavailable or the company’s delisted.
Price
₪50.23
Loss Chance
58.4%
0.94JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (25)
Recent Business Performance (42)
Financial Strength (32)
Return to Shareholders (13)
Competitive Advantage (23)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Revenue and EarningEarning loss detected in 2023
Operating MarginInconsistent
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
0.94
100.00%
1.94
495.39%
1.94
495.39%
COMPANY DESCRIPTION
As of April 30, 2024, Panaxia Labs Israel Ltd was acquired by Barak Investment House Ltd, in a reverse merger transaction. Panaxia Labs Israel Ltd provides pharmaceutical solutions for patients and physicians in Israel and internationally. It offers pharma-grade smokeless cannabis products, such as oral tablets, orodispersible tablets, sublingual tablets, oral oils, sublingual drops, solution for inhalation, pastilles, topicals, suppositories, and cannabis extracts in ethanol under the NAXIVA – PANAXOL, NAXIVA-PANAXOL-ONKO, PANAXIR SENSE, PANAXIR, Axiban, Tikva, Ultra Health, and Salus brands. Panaxia Labs Israel Ltd was incorporated in 2005 and is based in Lod, Israel.